In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci.
Using a checkerboard assay, ampicillin, vancomycin, and RP 59500, each in combination with chloramphenicol, were tested for synergy against 23 isolates of vancomycin-resistant enterococci. Additive effects were seen in 62.5% of the isolates when exposed to chloramphenicol plus RP 59500. Additive effects were observed in 20% and 15% of isolates with chloramphenicol plus vancomycin or ampicillin, respectively. No antagonism was noted.
Messick
C R
CR
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago 60612, USA.
Pendland
S L
SL
D000667:Ampicillin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002701:Chloramphenicol / Q000008:administration & dosage*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D016984:Enterococcus faecium / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000008:administration & dosage; D014640:Vancomycin / Q000008:administration & dosage*; D014769:Virginiamycin / Q000008:administration & dosage*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D002701:Chloramphenicol; D014640:Vancomycin; D000667:Ampicillin